Fidelity Investments
NGNE icon

Fidelity Investments’s Neurogene NGNE Stock Holding History

Fidelity Investments’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.71M Buy
382,647
+252,318
+194% +$4.89M ﹤0.01% 2136
2025
Q4 		$2.68M Buy
130,329
+14,779
+13% +$368K ﹤0.01% 2502
2025
Q3 		$2M Sell
115,550
-352,926
-75% -$7.09M ﹤0.01% 2544
2025
Q2 		$7M Buy
468,476
+5,597
+1% +$87.8K ﹤0.01% 2056
2025
Q1 		$5.42M Sell
462,879
-397,454
-46% -$6.9M ﹤0.01% 2115
2024
Q4 		$19.7M Buy
860,333
+128,532
+18% +$4.78M ﹤0.01% 1734
2024
Q3 		$30.7M Buy
731,801
+659,515
+912% +$25.6M ﹤0.01% 1561
2024
Q2 		$2.63M Buy
+72,286
New +$2.55M ﹤0.01% 2277
2022
Q3 		– Hold
0
– – – 5235
2022
Q2 		– Sell
-60
Closed -$1.46K – 5304
2022
Q1 		$2K Buy
+60
New +$3.5K ﹤0.01% 4686

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Fidelity Investments's NGNE Position: Q1 2026 in Review

Fidelity Investments increased its Neurogene (NGNE) stake by 194% in Q1 2026, buying an estimated $4.89M and bringing the position to 382,647 shares worth $7.71M. The position accounts for ﹤0.01% of the portfolio, ranked #2136.

Fidelity Investments first reported a position in NGNE in Q1 2022 and has held it in 9 quarters since. The position peaked at $30.7M in Q3 2024. 96 funds tracked by Wall St. Rank hold NGNE as of Q1 2026.

  • Fidelity Investments held 382,647 shares of Neurogene worth $7.71M as of Q1 2026.
  • Fidelity Investments bought 252,318 Neurogene shares in Q1 2026, an estimated $4.89M.
  • Neurogene made up ﹤0.01% of Fidelity Investments's portfolio in Q1 2026, its #2136 holding.
  • Fidelity Investments first reported a position in Neurogene in Q1 2022 and has held it in 9 quarters since.
  • Fidelity Investments's Neurogene position peaked at $30.7M in Q3 2024.
  • 96 funds tracked by Wall St. Rank held Neurogene as of Q1 2026.

Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.